Special issue on recent progress with hPSC-derived cardiovascular cells for organoids, engineered myocardium, drug discovery, disease models, and therapy
Pflugers Arch. 2021 Jul;473(7):983-988.
doi: 10.1007/s00424-021-02594-3.
Epub 2021 Jun 16.
1 Department of Biomedical Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, MD, 21205, USA. [email protected].
2 PhyMedExp, University of Montpellier, INSERM, CNRS, Montpellier, France. [email protected].
3 CAS Key Laboratory of Tissue Microenvironment & Tumor, Laboratory of Molecular Cardiology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences (CAS), CAS, Shanghai, 200031, People's Republic of China. [email protected].
4 Translational Medical Center for Stem Cell Therapy & Institute for Heart Failure and Regenerative Medicine, Shanghai East Hospital, Tongji University School of Medicine and Shanghai Institute of Stem Cell Research and Clinical Translation, Shanghai, 200123, People's Republic of China. [email protected].
5 Institute for Stem Cell and Regeneration, CAS, Beijing, 100101, People's Republic of China. [email protected].